ST Genesia
The Stago Group’s Thrombinoscope, Tcoag and Stago teams united to share their skills and expertise to work on this joint project, the ST Genesia.
ST Genesia is an automated analyser, based on the same principles as the CAT system, which measures thrombin generation.
Designed to support clinical applications in the lab, the key difference between systems is that CAT’s main purpose is for research and development.
ST Genesia aims at standardising and automating the thrombin generation test in order to make it widely accessable and available for use in in-vitro diagnostics (IVD). ST Genesia is designed to add to the information usually provided by routine tests (TP, TCA, etc.) or specialised tests (Anti-Xa, ECA) and offer an improved assessment of thrombotic and haemorrhagic risks to improve patient care.
A range of reagents specifically developed for ST Genesia is available:
- STG-ThromboScreen: Thrombin generation assessment in patients who are likely to suffer from thrombophilia.
- STG-BleedScreen*: Thrombin generation assessment in patients with bleeding risk, such as haemophiliacs.
- STG-DrugScreen*: Assessment of the effect of anticoagulants on treated patients, which could be useful for people at risk of drug accumulation (impaired renal function, people over 75, etc.).
Don’t hesitate to get in touch with your local representative for more information.
How is the measurement made?
The Thrombin Generation experiment is undertaken on a sample of plasma, which is commonly platelet poor. To this an initiator is added and the rate of thrombin generation is measured by the ability of the de novo thrombin to cleave a peptide from a fluorophore and induce fluorescence in the sample. The rate of development of the fluorescence is proportional to the thrombin present and is measured by the instrument to produce a time-trace known as a thrombogram. Watch the video below to see this in action!